TXG 10x Genomics, Inc.

51.80USD-9.72%Mkt Cap: 6.81B USDP/E: —

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia P…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap6.81B USD
Enterprise Value7.05B USD
Revenue (TTM)618.58M USD
Gross Profit443.88M USD
Net Income (TTM)-43.54M USD
Revenue/Share4.80 USD
Last Price51.80 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.2K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)597.67
PEG—
EV/EBITDA-265.86
EV/Revenue11.39
P/S11.01
P/B8.13
EPS (TTM)-0.52 USD
EPS (Forward)0.09 USD
52W Range
13.5843% of range102.81
52W High102.81 USD
52W Low13.58 USD
Profitability
Gross Margin69.05%
Oper. Margin-10.62%
EBITDA Margin-4.29%
Profit Margin-6.77%
ROE-5.47%
ROA-4.18%
ROIC-31.04%
ROCE-12.49%
Growth
Revenue Growth1.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF136.05M USD
CapEx (TTM)5.93M USD
FCF Margin19.86%
FCF Yield1.80%
Net Debt-499.89M USD
Net Debt/EBITDA18.86
Net Debt/FCF-4.07
Balance Sheet
Debt/Equity0.11
Current Ratio5.12
Quick Ratio4.52
Book Value/Sh6.37 USD
Cash/Share4.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.4 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)68.14 USD
Upside (mean)+31.5%
Target Range50.00 USD – 100.00 USD
50.00+31.5% to mean100.00
# Analysts14
Ownership
Shares Out.121.46M
Float119.47M
Insiders1.40%
Institutions114.55%
Short Interest
Short Ratio3.1d
Short % Float13.85%
Short % Out.9.48%
Shares Short12.47M
Short (prev mo.)15.37M
Technical
SMA 5073.38 (-29.4%)
SMA 20043.12 (+20.1%)
Beta2.03
S&P 52W Chg12.00%
Avg Vol (30d)3.23M
Avg Vol (10d)3.05M
Technical Indicators
RSI (14)35.2
MACD-4.8732
MACD Signal-4.0352
MACD Hist.-0.8380
BB Upper82.08 USD
BB Middle64.14 USD
BB Lower46.20 USD
BB Width55.94%
ATR (14)6.000 USD
Vol Ratio (20d)1.05x

About 10x Genomics (NASDAQ: TXG)

›

10x Genomics (NASDAQ: TXG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,178 employees.

The shares were at 51.80 USD on 20 November 2026, up 298.5% over 52 weeks. Its 52-week range is 13.58 USD to 102.81 USD: the price is 49.6% below the high and 281.4% above the low.

Its market capitalisation is 6.81B USD.

10x Genomics reports return on equity of -5.5%, an operating margin of -10.6% and revenue up 1.1% year over year.

It holds more cash than debt, a net cash position of 499.89M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 68.14 USD is 31.5% above the current price. The next earnings report is expected on 11 February 2027.